Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin N-terminal domain-containing protein 2 (CCNP)
- Target
- CCNP
- Molecular classification
- Cyclin, Cell cycle regulator, Cyclin-dependent protein serine/threonine kinase regulator, Atypical cyclin
01
Overview
Cyclin N-terminal domain-containing protein 2 (CCNP, also known as Cyclin P and CNTD2) is an atypical cyclin, part of the cyclin family of proteins that regulate the cell cycle via interaction with cyclin-dependent kinases (CDKs)[1][3]. Unlike canonical cyclins, CCNP possesses a conserved “cyclin box” but its specific CDK partners and biological functions are not fully elucidated[1]. High expression of CCNP has been found in several cancers, including colon, lung, and especially bladder cancer, where it may function as a tumor oncogene and serve as a prognostic biomarker associated with adverse outcomes[1]. Functional associations include involvement in mitotic nuclear division, DNA replication, RNA polymerase activity, base excision repair, homologous recombination, and regulation of cell proliferation and migration[1][3]. While currently no drugs directly target CCNP, it is considered a candidate therapeutic target due to its cancer-related expression profile[1][3].
- Other names
- Cyclin PCCNPCNTD2FLJ13265Cyclin N-terminal domain containing 2Cyclin N-terminal domain-containing protein 2
02
Biological functions
Cell cycle regulation (especially G1/S transition)Regulation of cell proliferation and migrationCell divisionDNA replicationRNA polymerase activityBase excision repairHomologous recombination
03
Disease associations
Cancer (prognostic biomarker and possible oncogenic role in colon, lung, and bladder cancer)Combined oxidative phosphorylation deficiency 8 (OMIM disease association)
04
Biomarkers
CCNP/CNTD2 expression levels (elevated expression is a potential adverse prognostic biomarker in bladder, colon, and lung cancer)
Beyond the preview
Go deeper on Cyclin N-terminal domain-containing protein 2 (CCNP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin N-terminal domain-containing protein 2 (CCNP).